GU Cancers 2019 | Non-clear cell sarcamatoid kidney cancer treatment updates

While there have been significant advances in the treatment for clear cell renal cell carcinoma (RCC), effective agents targeting non-clear cell RCC remains poorly defined given the rarity of the disease. Rana McKay, MD, of the University of California San Diego, San Diego, CA, talks about the Phase II, single-arm study (NCT02724878) that she and her colleagues conducted, investigating the efficacy of atezolizumab plus bevacizumab in non-clear cell and sarcomatoid differentiation RCC. This video was taken at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA.